A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
Inclusion Criteria:
Exclusion Criteria:
OYS, 90029, Finland
Kasuga-shi, Fukuoka 816-0864, Japan
Fujioka-shi, Gunma 375-0015, Japan
Takasaki-shi, Gunma 370-0829, Japan
Kawanishi-shi, Hyōgo 666-0125, Japan
Hitachi-shi, Ibaraki 317-0077, Japan
Koga-shi, Ibaraki 306-0041, Japan
Komatsu-shi, Ishikawa-ken 923-8560, Japan
Ina-shi, Nagano 396-8555, Japan
Matsumoto-shi, Nagano 390-0848, Japan
Suwa-shi, Nagano 392-8510, Japan
Ibaraki-shi, Osaka 567-0876, Japan
Toyonaka-shi, Osaka 560-0082, Japan
Hanyu-shi, Saitama 348-8505, Japan
Sayama-shi, Saitama 350-1305, Japan
Toda-shi, Saitama 335-0023, Japan
Chiyoda-ku, Tokyo 101-0041, Japan
Hachioji-shi, Tokyo 192-0918, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Shinagawa-ku, Tokyo 141-0001, Japan
Toshima-ku, Tokyo 171-0021, Japan